4 - Forte Biosciences, Inc. (0001419041) (Issuer)

4 - Forte Biosciences, Inc. (0001419041) (Issuer)

4 - Forte Biosciences, Inc. (0001419041) (Issuer)

4 - Forte Biosciences, Inc. (0001419041) (Issuer)

3 - Forte Biosciences, Inc. (0001419041) (Issuer)

3 - Forte Biosciences, Inc. (0001419041) (Issuer)

4 - Forte Biosciences, Inc. (0001419041) (Issuer)

4 - Forte Biosciences, Inc. (0001419041) (Issuer)

4 - Forte Biosciences, Inc. (0001419041) (Issuer)

4 - Forte Biosciences, Inc. (0001419041) (Issuer)

Brookline Capital analyst Kumaraguru Raja initiates coverage on Forte Biosciences (NASDAQ:FBRX) with a Buy rating and announces Price Target of $4.

Forte Biosciences (NASDAQ:FBRX) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.17) by 88.24 percent.

Ladenburg Thalmann analyst Michael Higgins upgrades Forte Biosciences (NASDAQ:FBRX) from Neutral to Buy and announces $2.75 price target.

2023 Operating ResultsResearch and development expenses were $21.9 million for the year ended December 31, 2023, compared to $5.6 million during the same period in 2022. The increase of $16.3 million was primarily due to a net increase of approximately $9.9 million in manufacturing expense, a net increase of approximately $6.0 million in preclinical and clinical expenses as our FB-102 program entered the clinic, and a net increase in payroll and related expenses of approximately $0.4 million primarily due to an increase in headcount.General and administrative expenses were $10.6 million for the year ended December 31, 2023, compared to $8.3 million for the same period in 2022. The increase o

 Funicular Funds has a 5.59% stake in Forte Biosciences

Gainers Alaunos Therapeutics (NASDAQ:TCRT) stock rose 20.9% to $0.06 during Friday's after-market session. The company's market cap stands at $13.2 million. Impel Pharmaceuticals (NASDAQ:IMPL) shares rose 11.98% to $0.27. The company's market cap stands at $6.4 million. I-MAB (NASDAQ:IMAB) shares increased by 7.19% to $1.49. The company's market cap stands at $123.1 million. Genprex (NASDAQ:GNPX) stock rose 6.63% to $0.23. The company's market cap stands at $13.3 million. Ikena Oncology (NASDAQ:IKNA) shares rose 6.59% to $2.1. The company's market cap stands at $101.3 million. Adaptimmune Therapeutics (NASDAQ:ADAP) stock increased by 6.22% to $0.48. The market value of their outstandin

The Dow Jones index closed higher by over 150 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. OLB Group The Trade: The OLB Group, Inc. (NASDAQ:OLB) Chairman and CEO Ronny Yakov acquired a total of 22,315 shares an average price of $0.75. To acquire these shares, it cost around $16,739. What’s Happening: On Nov. 15, the company posted a

The Dow Jones closed higher by over 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Forte Biosciences The Trade: Forte Biosciences, Inc. (NASDAQ:FBRX) Director Paul A Wagner acquired a total of 51,203 shares an average price of $0.60. To acquire these shares, it cost around $30,468. What’s Happening: On Nov. 13, Forte Biosciences pos

The Dow Jones closed higher by over 180 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Beasley Broadcast The Trade: Beasley Broadcast Group, Inc. (NASDAQ:BBGI) CEO Caroline Beasley acquired a total of 14,285 shares an average price of $0.73. To acquire these shares, it cost around $10,428. What’s Happening: Beasley Broadcast Group pos

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced an oversubscribed $53 million equity financing to support the continuing clinical advancement of FB102. "We are appreciative of the support from new and existing investors including OrbiMed, Janus Henderson Investors, Tybourne Capital Management, Alger, Ikarian Capital, LLC, BVF Partners LP, and The Red Hook Fund LP. This financing by high quality institutional investors is transformative for Forte and highlights the meaningful potential for FB102. As a result of the financing, Forte is well capitalized to continue ad

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced third quarter 2024 results and provided a business update. Third Quarter 2024 Business Highlights "We continue to make excellent progress with FB102 and have begun dosing patients in a celiac disease clinical trial. In addition to safety and tolerability, we will be assessing the histological impact as well as a variety of other activity parameters. The topline data is expected to readout in the second quarter of 2025," said Paul Wagner, Ph.D., Chairman and Chief Executive Officer of Forte Biosciences. "Based on the

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced second quarter 2024 results and provided a business update. Second Quarter 2024 Business Highlights "Forte continues to make excellent progress with FB102, our anti-CD122 monoclonal antibody therapeutic candidate. The SAD/MAD phase 1 healthy volunteer study has successfully completed and FB102 has demonstrated a good safety profile," said Paul Wagner, Ph.D., Chairman and Chief Executive Officer of Forte Biosciences. "Based on the successful completion of the phase 1 healthy volunteer cohorts, Forte is initiating a p

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte's Board of Directors approved the grant of equity awards to purchase a total of 70,000 shares of common stock to new non-executive employees as a material inducement to such individuals accepting employment with the Company, with each such award vesting over four years, with twenty-five percent vesting on the one-year anniversary of the applicable

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced first quarter 2024 results and provided a business update. First Quarter 2024 Business Highlights "Forte continues to make excellent progress with FB102. As we indicated last quarter, the single ascending dose (SAD) portion of the FB102 phase 1 trial was successfully completed. We expect the dosing of the multiple ascending dose (MAD) cohorts of the phase 1 trial in the healthy volunteers to complete around mid-year. To date, FB102 has demonstrated a good safety profile, including in the MAD cohorts," said Paul Wagn

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its 2023 results and provided a business update. 2023 Business Highlights "Forte achieved a major milestone by advancing FB-102 into the clinic and beating the timelines we targeted in our third quarter business update. The single ascending dose (SAD) portion of the FB-102 phase 1 trial was successfully completed and dosing has begun in the multiple ascending dose (MAD) cohorts." said Paul Wagner, Ph.D., Chairman and Chief Executive Officer of Forte Biosciences. "I am deeply appreciative of the talented Forte team t

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a biopharmaceutical company focused on autoimmune diseases today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte's Board of Directors approved the grant of an equity award to purchase 25,000 shares of common stock to a new non-executive employee as a material inducement to such individual's accepting employment with the Company, with such award vesting over four years, with twenty-five percent vesting on the one-year anniversary of the grant date and the remaining seventy-five percent vesting i

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced third quarter 2023 results and provided a business update. Third Quarter 2023 Business Highlights "The third quarter of 2023 was defined by continued solid progress on FB-102," said Paul Wagner, Ph.D., Chairman and Chief Executive Officer of Forte Biosciences. "Based on our preclinical data, we continue to believe that FB-102 is a best-in-class anti-CD122 antibody with broad therapeutic potential. Given the support of our new investors, we are in a strong position to advance FB-102 into human clinical trials by early 2024 and look

Both Leading Independent Proxy Advisory Firms Conclude Forte's Poor Performance and Dilutive, Anti-Stockholder Actions Under Chairman and CEO Dr. Paul Wagner's Leadership Indicate Boardroom Change is Urgently Needed Glass Lewis Recommends Stockholders Vote FOR the Group's Director Candidates – Michael Hacke and Chris McIntyre – Noting They Would Bring Value-Additive Capital Allocation and Investment Experience to the Company's Board Glass Lewis Acknowledges Forte's "Entrenched Board" is in Dire "Need of Fresh Perspectives," Necessitating Chairman and CEO Dr. Paul Wagner and Dr. Lawrence Eichenfield's Removal Investors are Encouraged to Vote for Michael Hacke and Chris McIntyre on the

Exposes Misrepresentations and Distortions Included in Forte's Recent Presentation Encourages Stockholders to Vote for Independent Director Candidates Michael Hacke and Chris McIntyre on the WHITE Proxy Card Ahead of Forte's Upcoming Annual Meeting on September 19th Camac Partners, LLC ("Camac") and ATG Capital Management, LLC ("ATG") (together with the other participants in their solicitation, the "Concerned Stockholders," the "Group" or "we") collectively own approximately 8.5% of the outstanding common stock of Forte Biosciences, Inc. (NASDAQ:FBRX) ("Forte" or the "Company"). Today, the Group and its independent director candidates – Michael Hacke and Chris McIntyre – responded to mi

Dr. Brun also appointed as Chairperson of Jasper Research and Development Committee and to Compensation Committee Board member Vishal Kapoor appointed to Jasper Audit and Compensation Committees REDWOOD CITY, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of Scott Brun, M.D., to Jasper's Board of Directors. Dr. Bru

 -FB-102 Continues to Advance Towards the Clinic and Holds Significant Market Potential Across a Variety of Indications- -Leadership Strengthened with the Appointment of Scott Brun, M.D. to the Board of Directors- -Ended third quarter 2022 with approximately $44.0 million in cash and cash equivalents- Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced third quarter 2022 results and provided a business update. "Forte is making excellent progress with its lead program FB-102, which is a direct result of the team's hard work and diligent efforts. FB-102 holds significant potential in a variety of indicatio

-Forte Leadership is Significantly Strengthened with the Appointment of Dr. Scott Brun, M.D. to the Board of Directors Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), announced today that Dr. Scott Brun, M.D. has been appointed to the Forte Biosciences Board of Directors. Dr. Brun is currently a Venture Partner at Abingworth and in addition to his consulting practice, he is also a Senior Advisor for Horizon Therapeutics, and a Senior Medical Advisor at Launch Therapeutics. Dr. Brun previously served in numerous executive capacities at AbbVie, most recently as Head of AbbVie Ventures. In Dr. Brun's previous role as Head of Product Development at Abbvie, he led the global organi

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a biopharmaceutical company focused on autoimmune diseases announces that Dr. Hubert Chen, MD has joined the company as Chief Scientific Officer and President. "Dr. Chen is a very accomplished drug development scientist and physician and we are very fortunate that he has agreed to join the Forte team," said Paul Wagner, Ph.D., CEO of Forte Biosciences. "This is a very exciting time for Forte and having Dr. Chen join us in this important leadership position reinforces our confidence in the future of Forte." Prior to joining Forte, Dr. Chen was the Chief Medical Officer of Metacrine, a clinical-stage company focused on the treatmen

Ladenburg Thalmann upgraded Forte Biosciences from Neutral to Buy and set a new price target of $2.75

Chardan Capital Markets upgraded Forte Biosciences from Sell to Buy and set a new price target of $3.50 from $4.00 previously

Chardan Capital upgraded Forte Biosciences from Sell to Neutral and set a new price target of $3.50 from $4.00 previously

Brookline Capital downgraded Forte Biosciences from Buy to Hold

Ladenburg Thalmann downgraded Forte Biosciences from Buy to Neutral

Chardan Capital Markets downgraded Forte Biosciences from Buy to Sell and set a new price target of $4.00 from $105.00 previously

Truist downgraded Forte Biosciences from Buy to Hold and set a new price target of $4.00

B. Riley Securities downgraded Forte Biosciences from Buy to Neutral and set a new price target of $3.00

Truist Securities downgraded Forte Biosciences from Buy to Hold

B. Riley Securities initiated coverage of Forte Biosciences with a rating of Buy and set a new price target of $73.00

4 - Forte Biosciences, Inc. (0001419041) (Issuer)

4 - Forte Biosciences, Inc. (0001419041) (Issuer)

4 - Forte Biosciences, Inc. (0001419041) (Issuer)

4 - Forte Biosciences, Inc. (0001419041) (Issuer)

4 - Forte Biosciences, Inc. (0001419041) (Issuer)